Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of tinlarebant in adolescents with Stargardt disease
NL-OMON60822Phase 3Completed
- Sponsor
- Belite Bio, Inc
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of tinlarebant in Fundus Flavimaculatus (FF), sponsored by Belite Bio, Inc. Primary endpoint: Annualized rate of lesion growth in aggregate area of atrophy. Started Jun 2023; status: completed.
02
Drugs
tinlarebant
03
Conditions
Fundus Flavimaculatus (FF)
Beyond the preview
Go deeper on NL-OMON60822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60822.